Revealing the Mechanism of Natural Product-induced Immunogenic Cell Death: Opening a New Chapter in Tumor Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 24

PMID 39445013

Authors

Yukun Chen

Zhenzhi Wang

Chi Zhang

Yisa Su

Tian Zhou

Kaiwen Hu

Affiliations

Soon will be listed here.

Abstract

This review underscores the role of natural products in inducing immunogenic cell death (ICD) as a key strategy in tumor immunotherapy. It reveals that natural products can activate ICD through multiple pathways-apoptosis, autophagy, pyroptosis, and necroptosis-leading to the release of danger-associated molecular patterns (DAMPs), dendritic cell activation, and improved antigen presentation, which together stimulate a potent anti-tumor immune response. The study also demonstrates the enhanced therapeutic potential of combining natural products with immune checkpoint inhibitors. With a focus on translating preclinical findings into clinical practice, this review consolidates recent discoveries and suggests future research paths, offering both theoretical insights and practical guidance for advancing cancer immunotherapy.

References

Szeto G, Finley S . Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019; 5(7):400-410. PMC: 7467854. DOI: 10.1016/j.trecan.2019.05.010. View

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

Lefler D, Manobianco S, Bashir B . Immunotherapy resistance in solid tumors: mechanisms and potential solutions. Cancer Biol Ther. 2024; 25(1):2315655. PMC: 10896138. DOI: 10.1080/15384047.2024.2315655. View

Ghiringhelli F, Rebe C . Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application. Immunol Rev. 2023; 321(1):335-349. DOI: 10.1111/imr.13263. View

Peng L, Yu F, Shen R, Zhou W, Wang D, Jiang Q . Glutathione Consumptive Dual-Sensitive Lipid-Composite Nanoparticles Induce Immunogenic Cell Death for Enhanced Breast Tumor Therapy. Mol Pharm. 2023; 21(1):113-125. DOI: 10.1021/acs.molpharmaceut.3c00518. View

Zhang Y, Yang S, Yang Y, Liu T . Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells. Infect Agent Cancer. 2019; 14:27. PMC: 6798484. DOI: 10.1186/s13027-019-0247-4. View

Choi M, Shin J, Lee C, Chung J, Kim M, Yan X . Immunogenic cell death in cancer immunotherapy. BMB Rep. 2023; 56(5):275-286. PMC: 10230015. View

Aaes T, Vandenabeele P . The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death Differ. 2020; 28(3):843-860. PMC: 7937679. DOI: 10.1038/s41418-020-00658-y. View

Ren B, Kwah M, Liu C, Ma Z, Shanmugam M, Ding L . Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Lett. 2021; 515:63-72. DOI: 10.1016/j.canlet.2021.05.001. View

10.

Arimoto K, Miyauchi S, Liu M, Zhang D . Emerging role of immunogenic cell death in cancer immunotherapy. Front Immunol. 2024; 15:1390263. PMC: 11116615. DOI: 10.3389/fimmu.2024.1390263. View

11.

Pan H, Liu P, Kroemer G, Kepp O . Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy. Int Rev Cell Mol Biol. 2024; 382:279-294. DOI: 10.1016/bs.ircmb.2023.06.001. View

12.

Ding D, Jiang X . Advances in Immunogenic Cell Death for Cancer Immunotherapy. Small Methods. 2023; 7(5):e2300354. DOI: 10.1002/smtd.202300354. View

13.

Sun M, Ye Y, Xiao L, Duan X, Zhang Y, Zhang H . Anticancer effects of ginsenoside Rg3 (Review). Int J Mol Med. 2017; 39(3):507-518. DOI: 10.3892/ijmm.2017.2857. View

14.

Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z . Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med. 2019; 23(8):4854-4865. PMC: 6653385. DOI: 10.1111/jcmm.14356. View

15.

Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W . Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023; 22(1):58. PMC: 10029244. DOI: 10.1186/s12943-023-01725-x. View

16.

Roussot N, Ghiringhelli F, Rebe C . Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment. Cells. 2022; 11(22). PMC: 9688834. DOI: 10.3390/cells11223672. View

17.

Wang Z, Little N, Chen J, Lambesis K, Le K, Han W . Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat Nanotechnol. 2021; 16(10):1130-1140. PMC: 8855709. DOI: 10.1038/s41565-021-00950-z. View

18.

Gumber D, Wang L . Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022; 77:103941. PMC: 8927848. DOI: 10.1016/j.ebiom.2022.103941. View

19.

Tuli H, Rath P, Chauhan A, Parashar G, Parashar N, Joshi H . Wogonin, as a potent anticancer compound: From chemistry to cellular interactions. Exp Biol Med (Maywood). 2023; 248(9):820-828. PMC: 10468645. DOI: 10.1177/15353702231179961. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View